3CL
Todos has finalized a new agreement with
Under the terms of the new license agreement, wholly-owned subsidiary 3CL
With this signed agreement now in place, the Company is now able to swiftly implement our strategy of crowdfunding within the 3CL Pharma entity to fund a Long COVID clinical trial. We expect to have announcements about the crowdfunding details, as well as product updates for Tollovid and business plan updates for 3CL Pharma in the coming weeks.
With the ending of the public health emergency (PHE) in
As a result of increased risk of cancer and Alzheimer’s among Long COVID patients, we believe that our proprietary Videssa™ breast cancer and LymPro Alzheimer’s blood tests will help arm Long COVID patients and all patients with additional tools to be proactive with their healthcare. We intend to initially bring these tests to market through Laboratory Developed Tests (LDTs).
Corporate Structure
The Company intends to create value for its shareholders through its equity ownership in 3CL Pharma that will allow it to offset its outstanding liabilities and capture the full value of the 3CL Pharma product offering for the Long COVID community via crowdfunding and subsequent listing of 3CL Pharma.
For more information, please visit todosmedical.com. For more information on the Company’s dietary supplement that provides immune support with 3CL protease inhibition, please visit www.mytollovid.com.
About
Founded in
Todos is also developing blood tests for the early detection of neurodegenerative disorders, such as Alzheimer's disease. The Lymphocyte Proliferation Test (LymPro Test™) is a diagnostic blood test that determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as a surrogate for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.
Todos formed 3CL Pharma USA, Inc. 2022 to consolidate the intellectual property surrounding 3CL protease–based diagnostic testing and development of 3CL protease botanical and pharmaceutical inhibitors that target a fundamental reproductive mechanism of coronaviruses. 3CL Pharma, through Todos’ brand, has commercialized the 3CL protease inhibitor immune support dietary supplement Tollovid™ in
To purchase Tollovid please visit Amazon or www.MyTollovid.com.
For more information, please visit https://todosmedical.com/.
Forward-looking Statements
Certain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law,
Todos Corporate and Investor Contact:
President & CEO
gerald@todosmedical.com
Source:
2023 GlobeNewswire, Inc., source